Updated on 7 October 2013
Bliss Pharmaceuticals has said that it complies with all norms laid down by the US FDA for manufacture of its products and maintains high international GMP standards
Singapore: Indian pharmaceutical company, Bliss Pharmaceuticals, denied the allegations made by the US FDA terming the malaria drugs manufactured and distributed by the company in Ghana as ‘fake'.
Dismissing the classification of the FDA that products of the company, which are distributed locally by Tobinco Pharmaceuticals in Ghana are fake, the company issued a statement.
"We will like to state emphatically that all our products have been subjected to stringent quality standards and meet the required accreditations in India. It is unfortunate that the FDA released a statement classifying our products as fake," the statement said.
The statement further added that the claim by the US FDA led to the blacklisting of the company manufactured medicinal products for the Ghanaian market. It said that Bliss complies with all norms laid down by the US FDA for manufacture of its products and maintains high international GMP standards.
The statement also clarified that the company has been working along with FDA authorities on all issues pertaining to compliance of regulatory requirements.